logo
logo
Search stocks & features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
EMA ScreenerEMA Screener
SMA ScreenerSMA Screener
WMA ScreenerWMA Screener
OHLC ScreenerOHLC Screener
Fibonacci ScreenerFibonacci Screener
VWAP ScreenerVWAP Screener
Pivot Point ScreenerPivot Point Screener
Overlay ScreenerOverlay Screener
Trend Indicator ScreenerTrend Indicator Screener
Volume Based Indicator ScreenerVolume Based Indicator Screener
Overbought/Sold ScreenerOverbought/Sold Screener
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Sector BoosterSector Booster
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
IPO CalendarIPO Calendar
Economic CalendarEconomic Calendar
Market closedRefreshes 15s
FDC

FDC

View MapTV Chart
381.00
19.55−4.88%
DAY379
₹381.00
400
52W313
₹381.00
528
Open392.00
Prev Close400.55
Bid380.98252
Ask381.03158
Volume631.1K+7%vs 20D avg
Valuation vs Sector
P/E Ratio▲ 1.6%
22.04vs Sector 21.70
lower = cheaper
P/B Ratio▲ 0.4%
2.50vs Sector 2.49
lower = cheaper
Div Yield
vs Sector
higher = more income
Market Cap₹6,165.62 Cr
P/E TTM27.35
Book Value₹140.11
EPS TTM₹13.85
ROCE15.9%
ROE2.85%
D/E0.01
Div Yield0%
Valuation

FDC Ltd valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for FDC Ltd, framed against the sector median so the premium or discount is obvious at a glance.

FDC Ltd trades at a P/E of 27.35×.

the price tag

Valuation

Market Cap
₹6,165.62 Cr
P/E Ratio
avg27.35
P/B Ratio
good2.96
EPS
13.85
the engine

Profitability

ROE
watch2.85%
ROCE
good15.9%
Net Margin
good10.85%
Op Margin
watch%
the trajectory

Growth

EPS 5Y
watch3.28%
Revenue 5Y
avg9.42%
Qtr Sales
avg1.59%
Qtr Profit
avg1.94%
the balance sheet

Financial Health

Debt / Equity
good0.01
Book Value
140.11
Div Yield
avg%
Promoter Hold.
good69.7%
Financials

FDC Ltd financials: P&L, balance sheet, cash flow, ratios.

Twelve years of audited numbers for FDC Ltd, switchable between annual and quarterly views, consolidated or standalone.

FDC Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,165.618 Cr and reported EPS of ₹13.85.

all values in ₹ Cr unless suffixed · source: company filings
Segment Analysis

FDC segment analysis: revenue and profit mix.

Disclosed business segments at FDC with their share of revenue and profit, switchable between consolidated and standalone reporting.

FDC discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Investment Thesis

FDC Ltd investment thesis: bull case, bear case, and the flip lines.

Why someone would buy FDC Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.

FDC Ltd's investment case rests on 5 positive markers and 6 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

  • FDC Ltd exhibits a robust promoter holding of 69.7%, signifying strong internal confidence and mitigating takeover risks. This high percentage assures investors of stability and long-term commitment.

  • The company maintains a conservative financial strategy, reflected in its exceptionally low debt-to-equity ratio of 0.01. This minimizes financial distress risks and enhances overall financial stability.

  • FDC demonstrates healthy profitability with a Return on Capital Employed (ROCE) of 15.90% and Return on Equity (ROE) of 11.80%, indicating efficient capital utilization and solid operational performance.

  • As a player in the Pharmaceuticals sector, FDC is well-positioned to capitalize on the growing global demand for healthcare products, driven by an aging population and increasing health awareness.

  • FDC's relatively smaller market capitalization of ₹7166 Cr, compared to larger industry peers, presents an opportunity for higher percentage growth through market share expansion and strategic product diversification.

bear case

What can break it.

  • FDC's stock price shows considerable volatility, with a 52-week high of ₹559 and a low of ₹359, indicating market uncertainty and potential risk for investors seeking stable returns.

  • Despite positive profit growth, FDC's Price-to-Earnings (PE) ratio of 26.60 is relatively high compared to some industry peers, suggesting a potential overvaluation and susceptibility to price corrections.

  • The company exhibits notably low quarterly sales growth of 1.59% and quarterly profit growth of 1.94%, significantly lagging behind many industry peers and raising concerns about competitive performance.

  • FDC faces intense competition from larger, well-established pharmaceutical companies like Sun Pharma and Divi's Lab, potentially limiting its market share growth and pricing power in key segments.

  • The highly regulated pharmaceutical industry exposes FDC to risks from adverse policy changes, stricter compliance requirements, and potential pricing pressures, impacting future revenue and profitability.

flip conditions

What would change my mind.

  • Trim if P/E re-rates above 36. The valuation cushion thins from there.

  • Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.

Shareholding

FDC shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in FDC — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Loading shareholding data...

Peers

FDC Ltd peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — FDC Ltd is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
Aarti Pharmalabs Ltd
583609.26L ₹ Cr
Best Profit Growth
Biofil Chemicals & Pharmaceuticals Ltd
1318.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %

Peer Comparison

Company Name
AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd
AARTIDRUGS
Aarti Drugs Ltd
AARTIPHARM
Aarti Pharmalabs Ltd
AJANTPHARM
Ajanta Pharma Ltd
AKUMS
Akums Drugs & Pharmaceuticals Ltd
ALBERTDAVD
Albert David Ltd
ALIVUS
Alivus Life Sciences Ltd
ALKEM
Alkem Laboratories Ltd
ALPA
Alpa Laboratories Ltd
AMRUTANJAN
Amrutanjan Health Care Ltd
APLLTD
Alembic Pharmaceuticals Ltd
ASTRAZEN
Astrazeneca Pharma India Ltd
AUROPHARMA
Aurobindo Pharma Ltd
BAFNAPH
Bafna Pharmaceuticals Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BALPHARMA
Bal Pharma Ltd
BIOCON
Biocon Ltd
BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd
BLISSGVS
Bliss GVS Pharma Ltd
BLUEJET
Blue Jet Healthcare Ltd
BROOKS
Brooks Laboratories Ltd
CAPLIPOINT
Caplin Point Laboratories Ltd
CIPLA
Cipla Ltd
COHANCE
Cohance Lifesciences Ltd
CONCORDBIO
Concord Biotech Ltd
DCAL
Dishman Carbogen Amcis Ltd
DIVISLAB
Divis Laboratories Ltd
DRREDDY
Dr Reddys Laboratories Ltd
EMCURE
Emcure Pharmaceuticals Ltd
ERIS
ERIS Lifesciences Ltd
FDC
FDC LtdCurrent Stock
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
GRANULES
Granules India Ltd
GUFICBIO
Gufic BioSciences Ltd
HALEOSLABS
Haleos Labs Limited
HESTERBIO
Hester Biosciences Ltd
HIKAL
Hikal Ltd
INDOCO
Indoco Remedies Ltd
INDSWFTLAB
Ind-Swift Laboratories Ltd
INNOVACAP
Innova Captab Ltd
IOLCP
IOL Chemicals & Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
JUBLPHARMA
Jubilant Pharmova Ltd
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran Ltd
KREBSBIO
Krebs Biochemicals & Industries Ltd
LASA
Lasa Supergenerics Ltd
LAURUSLABS
Laurus Labs Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
LUPIN
Lupin Ltd
LYKALABS
Lyka Labs Ltd
MANGALAM
Mangalam Drugs and Organics Ltd
MANKIND
Mankind Pharma Ltd
MARKSANS
Marksans Pharma Ltd
MEDICAMEQ
Medicamen Biotech Ltd
MEDICO
Medico Remedies Ltd
MOREPENLAB
Morepen Laboratories Ltd
NATCOPHARM
Natco Pharma Ltd
NECLIFE
Nectar Lifescience Ltd
NEULANDLAB
Neuland Laboratories Ltd
NGLFINE
NGL Fine Chem Ltd
ONESOURCE
OneSource Specialty Pharma Ltd
ORCHPHARMA
Orchid Pharma Ltd
ORTINGLOBE
Ortin Global Ltd
PANACEABIO
Panacea Biotec Ltd
PFIZER
Pfizer Ltd
PGHL
Procter & Gamble Health Ltd
PPLPHARMA
Piramal Pharma Ltd
RPGLIFE
RPG Life Sciences Ltd
SAILIFE
Sai Life Sciences Ltd
SANOFI
Sanofi India Ltd
SANOFICONR
Sanofi Consumer Healthcare India Ltd
SENORES
Senores Pharmaceuticals Ltd
SHILPAMED
Shilpa Medicare Ltd
SIGACHI
Sigachi Industries Ltd
SMSPHARMA
SMS Pharmaceuticals Ltd
SOLARA
Solara Active Pharma Sciences Ltd
SPARC
Sun Pharma Advanced Research Company Ltd
STAR
Strides Pharma Science Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SUPRIYA
Supriya Lifescience Ltd
SYNCOMF
Syncom Formulations (India) Ltd
THEMISMED
Themis Medicare Ltd
TORNTPHARM
Torrent Pharmaceuticals Ltd
UNICHEMLAB
Unichem Laboratories Ltd
VALIANTLAB
Valiant Laboratories Ltd
VENUSREM
Venus Remedies Ltd
VINEETLAB
Vineet Laboratories Ltd
VIYASH
Viyash Scientific Ltd
WANBURY
Wanbury Ltd
WINDLAS
Windlas Biotech Ltd
WOCKPHARMA
Wockhardt Ltd
ZIMLAB
Zim Laboratories Ltd
ZYDUSLIFE
Zydus Lifesciences Ltd
Technicals

FDC Ltd technical analysis: indicators, pivots and CPR.

Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for FDC Ltd — derived from the live tape, not yesterday's close.

FDC Ltd last traded at ₹381 with an intraday range of ₹379.4–₹399.95 — live indicator, pivot and CPR signals below.

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Live: ₹381.00
LevelPrice (₹)Distance% Δ
R4435.27+54.27+14.24%
R3414.72+33.72+8.85%
R2407.33+26.33+6.91%
R1394.17+13.17+3.46%
PIVOT386.785.781.52%
CURRENT381.00
S1332.52-48.48-12.73%
S2353.07-27.93-7.33%
S3366.23-14.77-3.88%
S4373.62-7.38-1.94%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 383.89P: 386.78TC: 389.67
R1
R2
R3
R4
indicator
LTP: 381.00
PDH: 421.00
PDL: 396.00
● Market Sentiment

FDC is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Wider, suggesting unlikely for trending moves

● Opening Range

Day's range: 382.15 ~ 399.95

● Price Position

Trading Below opening range, showing Bearishness

Delivery & Volume

FDC Ltd delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for FDC Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in FDC Ltd stood at 45.3% of traded volume, against a 20-day average of 51.0%.

Avg Delivery (20D)51%-5.7 ppt latest vs avg
Highest Delivery75.4%on 19 May
Avg Volume (20D)5.92 L20-day run-rate
Conviction Trend↓ Weakening-5.7 ppt latest read
Volume & Delivery · last 20 sessions
Filings & Concalls

FDC announcements: results, concalls, ratings, M&A.

Filings FDC sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

Corporate Actions

FDC dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue FDC has declared, sequenced by announce and record date.

FDC corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About FDC Ltd: business, sector, key facts.

What FDC Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

FDC Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: FDC, BSE: 531599.

FDC
Pharmaceuticals

FDC Ltd

NSE · FDC·BSE · 531599·www.fdcindia.com

FDC Limited is a pharmaceutical company with a long history, established in 1936 and headquartered in Mumbai, India. Its core business revolves around the manufacture and marketing of a wide range of pharmaceutical products both domestically within India and internationally. The company's product portfolio is extensive and caters to various therapeutic areas, demonstrating a diverse approach to market segments.

FDC's product offerings span a considerable spectrum of therapeutic categories. These include anti-infectives to combat infections, gastrointestinal medications for digestive health, and ophthalmic products for eye care. Furthermore, they produce vitamins, minerals, and dietary supplements targeting overall health and wellness. Their product line also extends to treatments for cardiac conditions, diabetes, respiratory illnesses, gynecological issues, dermatological problems, and pain management (analgesics). Beyond traditional pharmaceuticals, they also manufacture and market a range of nutraceuticals, including anti-oxidants, balanced energy and protein drinks.

The company leverages a portfolio of established brand names to market its products. These brands, such as Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal, represent a significant investment in brand recognition and consumer trust. This multi-brand strategy likely helps FDC target diverse market segments and consumer needs within the pharmaceutical and nutraceutical sectors.

In addition to finished pharmaceutical products, FDC also manufactures active pharmaceutical ingredients (APIs). This vertical integration provides the company with greater control over its supply chain and potentially allows for cost efficiencies and enhanced product quality. By controlling the production of core components, FDC likely mitigates risks associated with reliance on external API suppliers.

company facts
Founded / IPO07/08/1997
Employees6,659
SectorHealth Care
HeadquartersMumbai, MAHARASHTRA, IN
Market Cap₹6,165.62 Cr
Listed OnNATIONAL STOCK EXCHANGE OF INDIA
leadership22 on record
Mr. Uday Gurkar
Non-Executive Independent Chairman of the Board
Mr. Vijay Bhatt
Chief Financial Officer
Mr. Ameya Chandavarkar
Chief Executive Officer - International Business, Executive Director
Ms. Varsharani Katre
Compliance Officer, Company Secretary
Mr. Mohan Chandavarkar
Managing Director, Executive Director
Mr. Nandan Chandavarkar
Joint Managing Director, Executive Director
Mr. Ashok Chandavarkar
Executive Director
Ms. Nomita Chandavarkar
Non-Executive Non-Independent Director
Dr. Charuta Mandke
Additional Independent Director
Mr. Vijay Bhatt
Additional Non-Executive Independent Director
Dr. Mahesh Bijlani
Non-Executive Independent Director
Mr. Vijay Maniar
Non-Executive Independent Director
§ ∞ · Plainly Answered

Questions investors ask about FDC Ltd (FDC).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of FDC Ltd (FDC)?

The current share price of FDC Ltd (FDC) is ₹381. Today, the stock has declined by ₹19.55 (4.88%), trading in a range of ₹379.4 to ₹399.95. The stock opened at ₹392 with a trading volume of 6,31,093 shares.

02Is FDC Ltd stock a good investment for long-term?

FDC Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,165.62 crores, P/E ratio of 27.35, ROE of 2.85%, and ROCE of 15.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of FDC Ltd stock?

The 52-week high price of FDC Ltd (FDC) is ₹527.8, while the 52-week low is ₹312.95. Currently trading at ₹381, the stock is 31.7% away from its 52-week low and 27.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy FDC Ltd stock at the current price?

Whether to buy FDC Ltd stock at ₹381 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.35 and P/B ratio of N/A. Today's performance shows a loss of 4.88%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of FDC Ltd and when is the next dividend?

FDC Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹381, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of FDC Ltd?

FDC Ltd's key financial metrics include: P/E Ratio: 27.35, P/B Ratio: N/A, ROE: 2.85%, ROCE: 15.90%, Dividend Yield: 0.00%, EPS: ₹13.85, Book Value: ₹140.11, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹6,165.62 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is FDC Ltd stock performing today in the market?

FDC Ltd stock opened at ₹392 and is currently trading at ₹381, showing a decline of ₹19.55 (4.88%). The intraday high is ₹399.95 and low is ₹379.4. The trading volume stands at 6,31,093 shares, indicating moderate market participation today.

08What is the P/E ratio of FDC Ltd and what does it indicate?

FDC Ltd has a Price-to-Earnings (P/E) ratio of 27.35, which means investors are willing to pay ₹27.35 for every ₹1 of earnings. With an EPS of ₹13.85, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about FDC Ltd (FDC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.